Novel pharmacotherapy for fibromyalgia

Bibliography

• WOLFE F, ROSS K, ANDERSON J, RUSSELL IJ, HEBERT L: The prevalence and characteristics of fibromyalgia in the general population. Arthritis Rheum. (1995) 38(1):19-28.
   PubMed Web of Science ®Google Scholar
• WOLFE F, SMYTHE HA, YUNUS MB et al.: The American College of Rheumatology. Criteria for the Classification of Fibromyalgia. Report of the Multicenter Criteria Committee. Arthritis Rheum. (1990) 33(2):160-172.
   PubMed Web of Science ®Google Scholar
• CLAUW DJ: Fibromyalgia: more than just a musculoskeletal disease. Am. Fam. Physician (1995) 52(3):853-854.
   Web of Science ®Google Scholar
• JAIN AK, CARRUTHERS BM, VAN DE SANDE MI et al.: Fibromyalgia syndrome: Canadian clinical working case definition, diagnostic and treatment protocols – a consensus document. J. Musculoskeletal Pain (2003) 11:3-107.
   Web of Science ®Google Scholar
• ARNOLD LM: Biology and therapy of fibromyalgia: new therapies in fibromyalgia. Arthritis Res. Ther. (2006) 8(4):212.
   PubMed Web of Science ®Google Scholar
• HOLMAN AJ: Treatment of fibromyalgia: a changing of the guard. Women’s Health (2005) 1(3):409-420.
   Google Scholar
• LAWSON K: Emerging pharmacological therapies for fibromyalgia. Curr. Opin. Investig. Drugs (2006) 7(7):631-636.
   PubMed Web of Science ®Google Scholar
• CLAUW DJ, CROFFORD LJ: Chronic widespread pain and fibromyalgia: what we know, and what we need to know. Best Pract. Res. Clin. Rheumatol. (2003) 17(4):685-701.
   PubMed Web of Science ®Google Scholar
• MEASE P: Fibromyalgia syndrome: review of clinical presentation, pathogenesis, outcome measures, and treatment. J. Rheumatol. Suppl. (2005) 75:6-21.
   PubMedGoogle Scholar
• MEASE PJ, CLAUW DJ, ARNOLD LM et al.: Fibromyalgia syndrome. J. Rheumatol. (2005) 32(11):2270-2277.
   PubMed Web of Science ®Google Scholar
• PRICE DD, STAUD R: Neurobiology of fibromyalgia syndrome. J. Rheumatol. Suppl. (2005) 75:22-28.
   PubMedGoogle Scholar
• LEVINE JD, REICHLING DB: Fibromyalgia: the nerve of that disease. J. Rheumatol. Suppl. (2005) 75:29-37.
   PubMedGoogle Scholar
• KHASAR SG, GREEN PG, MIAO FJ, LEVINE JD: Vagal modulation of nociception is mediated by adrenomedullary epinephrine in the rat. Eur. J. Neurosci. (2003) 17(4):909-915.
   PubMed Web of Science ®Google Scholar
• MARTINEZ-LAVIN M, HERMOSILLO AG, ROSAS M, SOTO ME: Circadian studies of autonomic nervous balance in patients with fibromyalgia: a heart rate variability analysis. Arthritis Rheum. (1998) 41(11):1966-1971.
   PubMed Web of Science ®Google Scholar
• MARTINEZ-LAVIN M, HERMOSILLO AG: Autonomic nervous system dysfunction may explain the multisystem features of fibromyalgia. Semin. Arthritis Rheum. (2000) 29(4):197-199.
   PubMed Web of Science ®Google Scholar
• NASCHITZ JE, ROZENBAUM M, FIELDS MC et al.: Cardiovascular reactivity in fibromyalgia: evidence for pathogenic heterogeneity. J. Rheumatol. (2005) 32(2):335-339.
   PubMed Web of Science ®Google Scholar
• STAUD R, VIERCK CJ, ROBINSON ME, PRICE DD: Effects of the N-methyl-d-aspartate receptor antagonist dextromethorphan on temporal summation of pain are similar in fibromyalgia patients and normal control subjects. J. Pain (2005) 6(5):323-332.
   PubMed Web of Science ®Google Scholar
• VIERCK CJ Jr, STAUD R, PRICE DD, CANNON RL, MAUDERLI AP, MARTIN AD: The effect of maximal exercise on temporal summation of second pain (windup) in patients with fibromyalgia syndrome. J. Pain (2001) 2(6):334-344.
   PubMed Web of Science ®Google Scholar
• NEECK G, CROFFORD LJ: Neuroendocrine perturbations in fibromyalgia and chronic fatigue syndrome. Rheum. Dis. Clin. North Am. (2000) 26(4):989-1002.
   PubMed Web of Science ®Google Scholar
• JONES KD, DEODHAR P, LORENTZEN A, BENNETT RM, DEODHAR AA: Growth hormone perturbations in fibromyalgia: a review. Seminars in Rheumatology (2007) (In Press).
   Google Scholar
• JONES KD, DEODHAR AA, BURCKHART CS, PERRIN NA, HANSON GC, BENNETT RM: A combination of 6 months of treatment with pyridostigmine and triweekly exercise fails to improve insulin-like growth factor-1 levels in fibromyalgia, despite improvement in the acute growth hormone response to exercise. J. Rheum. (2007) 34(5):1103-1111.
   PubMed Web of Science ®Google Scholar
• BENNETT R: Fibromyalgia: present to future. Curr. Rheumatol. Rep. (2005) 7(5):371-376.
   PubMedGoogle Scholar
• ELVIN A, SIOSTEEN AK, NILSSON A, KOSEK E: Decreased muscle blood flow in fibromyalgia patients during standardised muscle exercise: a contrast media enhanced colour Doppler study. Eur. J. Pain (2006) 10(2):137-144.
   PubMed Web of Science ®Google Scholar
• STAUD R, VIERCK CJ, ROBINSON ME, PRICE DD: Overall fibromyalgia pain is predicted by ratings of local pain and pain-related negative affect – possible role of peripheral tissues. Rheumatology (2006) 45(11):1409-1415.
   PubMed Web of Science ®Google Scholar
• WILLIS WD: Role of neurotransmitters in sensitization of pain responses. Ann. NY Acad. Sci. (2001) 933:142-156.
   PubMed Web of Science ®Google Scholar
• SORENSEN J, BENGTSSON A, BACKMAN E, HENRIKSSON KG, BENGTSSON M: Pain analysis in patients with fibromyalgia. Effects of intravenous morphine, lidocaine, and ketamine. Scand. J. Rheumatol. (1995) 24(6):360-365.
   PubMed Web of Science ®Google Scholar
• SORENSEN J, BENGTSSON A, AHLNER J, HENRIKSSON KG, EKSELIUS L, BENGTSSON M: Fibromyalgia – are there different mechanisms in the processing of pain? A double blind crossover comparison of analgesic drugs. J. Rheumatol. (1997) 24(8):1615-1621.
   PubMed Web of Science ®Google Scholar
• GRAVEN-NIELSEN T, ASPEGREN-KENDALL S, HENRIKSSON KG et al.: Ketamine reduces muscle pain, temporal summation, and referred pain in fibromyalgia patients. Pain (2000) 85(3):483-491.
   PubMed Web of Science ®Google Scholar
• STAUD R, VIERCK CJ, CANNON RL, MAUDERLI AP, PRICE DD: Abnormal sensitization and temporal summation of second pain (wind-up) in patients with fibromyalgia syndrome. Pain (2001) 91(1-2):165-175.
   PubMed Web of Science ®Google Scholar
• KAPUR S, SEEMAN P: NMDA receptor antagonists ketamine and PCP have direct effects on the dopamine D2 and serotonin 5-HT2 receptors – implications for models of schizophrenia. Mol. Psychiatry (2002) 7(8):837-844.
   PubMed Web of Science ®Google Scholar
• SEEMAN P, KO F, TALLERICO T: Dopamine receptor contribution to the action of PCP, LSD and ketamine psychotomimetics. Mol. Psychiatry (2005) 10(9):877-883.
   PubMed Web of Science ®Google Scholar
• BARANIUK JN, WHALEN G, CUNNINGHAM J, CLAUW DJ: Cerebrospinal fluid levels of opioid peptides in fibromyalgia and chronic low back pain. BMC Musculoskelet. Disord. (2004) 5:48.
   PubMed Web of Science ®Google Scholar
• LARSON AA, GIOVENGO SL, RUSSELL IJ, MICHALEK JE: Changes in the concentrations of amino acids in the cerebrospinal fluid that correlate with pain in patients with fibromyalgia: implications for nitric oxide pathways. Pain (2000) 87(2):201-211.
   PubMed Web of Science ®Google Scholar
• RUSSELL IJ, ORR MD, LITTMAN B et al.: Elevated cerebrospinal fluid levels of substance P in patients with the fibromyalgia syndrome. Arthritis Rheum. (1994) 37(11):1593-1601.
   PubMed Web of Science ®Google Scholar
• GIOVENGO SL, RUSSELL IJ, LARSON AA: Increased concentrations of nerve growth factor in cerebrospinal fluid of patients with fibromyalgia. J. Rheumatol. (1999) 26(7):1564156-1564159.
   Google Scholar
• RUSSELL IJ, VAEROY H, JAVORS M, NYBERG F: Cerebrospinal fluid biogenic amine metabolites in fibromyalgia/fibrositis syndrome and rheumatoid arthritis. Arthritis Rheum. (1992) 35(5):550-556.
   PubMed Web of Science ®Google Scholar
• SHYU BC, KIRITSY-ROY JA, MORROW TJ, CASEY KL: Neurophysiological, pharmacological and behavioral evidence for medial thalamic mediation of cocaine-induced dopaminergic analgesia. Brain Res. (1992) 572:216-223.
   PubMed Web of Science ®Google Scholar
• CHUDLER EH, DONG WK: The role of the basal ganglia in nociception and pain. Pain (1995) 60(1):3-38.
   PubMed Web of Science ®Google Scholar
• LOPEZ-AVILA A, COFFEEN U, ORTEGA-LEGASPI JM, DEL ANGEL R, PELLICER F: Dopamine and NMDA systems modulate long-term nociception in the rat anterior cingulate cortex. Pain (2004) 111(1-2):136-143.
   PubMed Web of Science ®Google Scholar
• BURKEY AR, CARSTENS E, JASMIN L: Dopamine reuptake inhibition in the rostral agranular insular cortex produces antinociception. J. Neurosci. (1999) 19(10):4169-4179.
   PubMed Web of Science ®Google Scholar
• PANI L, PORCELLA A, GESSA GL: The role of stress in the pathophysiology of the dopaminergic system. Mol. Psychiatry (2000) 5(1):14-21.
   PubMed Web of Science ®Google Scholar
• WOOD PB: Stress and dopamine: implications for the pathophysiology of chronic widespread pain. Med. Hypotheses (2004) 62(3):420-424.
   PubMed Web of Science ®Google Scholar
• WOOD PB, PATTERSON JC, SUNDERLAND JJ, TAINTER KH, GLABUS MF, LILIEN DL: Reduced presynaptic dopamine activity in fibromyalgia syndrome demonstrated with PET: a pilot study. J. Pain (2007) 8(1):51-58.
   PubMed Web of Science ®Google Scholar
• SCOTT DJ, HEITZEG MM, KOEPPE RA, STOHLER CS, ZUBIETA JK: Variations in the human pain stress experience mediated by ventral and dorsal basal ganglia dopamine activity. J. Neurosci. (2006) 26(42):10789-10795.
   PubMed Web of Science ®Google Scholar
• WOOD PB, BUSHNELL MC, DAGHER A et al.: Disruption of dopaminergic reactivity in fibromyalgia demonstrated by 11C-raclopride/PET. Eur. J. Pain (2006) 10(Suppl. 1):S115 (Abstract).
   Google Scholar
• ALTIER N, STEWART J: Dopamine receptor antagonists in the nucleus accumbens attenuate analgesia induced by ventral tegmental area substance P or morphine and by nucleus accumbens amphetamine. J. Pharmacol. Exp. Ther. (1998) 285(1):208-215.
   PubMed Web of Science ®Google Scholar
• MENSE S: Neurobiological concepts of fibromyalgia – the possible role of descending spinal tracts. Scand. J. Rheumatol. Suppl. (2000) 113:24-29.
   PubMedGoogle Scholar
• HEFFEZ DS, ROSS RE, SHADE-ZELDOW Y et al.: Clinical evidence for cervical myelopathy due to Chiari malformation and spinal stenosis in a non-randomized group of patients with the diagnosis of fibromyalgia. Eur. Spine J. (2004) 13(6):516-523.
   PubMed Web of Science ®Google Scholar
• THIMINEUR M, KITAJ M, KRAVITZ E, KALIZEWSKI T, SOOD P: Functional abnormalities of the cervical cord and lower medulla and their effect on pain: observations in chronic pain patients with incidental mild Chiari I malformation and moderate to severe cervical cord compression. Clin. J. Pain (2002) 18(3):171-179.
   PubMed Web of Science ®Google Scholar
• URBAN MO, GEBHART GF: Supraspinal contributions to hyperalgesia. Proc. Natl. Acad. Sci. USA (1999) 96(14):7687-7692.
   PubMed Web of Science ®Google Scholar
• SUZUKI R, DICKENSON A: Spinal and supraspinal contributions to central sensitization in peripheral neuropathy. Neurosignals (2005) 14(4):175-181.
   PubMed Web of Science ®Google Scholar
• DAMSA C, BUMB A, BIANCHI-DEMICHELI F et al.: ‘Dopamine-dependent’ side effects of selective serotonin reuptake inhibitors: a clinical review. J. Clin. Psychiatry (2004) 65(8):1064-1068.
   PubMed Web of Science ®Google Scholar
• KIHARA T, IKEDA M: Effects of duloxetine, a new serotonin and norepinephrine uptake inhibitor, on extracellular monoamine levels in rat frontal cortex. J. Pharmacol. Exp. Ther. (1995) 272(1):177-183.
   PubMed Web of Science ®Google Scholar
• WEIKOP P, KEHR J, SCHEEL-KRUGER J: The role of α1- and α2-adrenoreceptors on venlafaxine-induced elevation of extracellular serotonin, noradrenaline and dopamine levels in the rat prefrontal cortex and hippocampus. J. Psychopharmacol. (2004) 18(3):395-403.
   PubMed Web of Science ®Google Scholar
• GENDREAU RM, THORN MD, GENDREAU JF et al.: Efficacy of milnacipran in patients with fibromyalgia. J. Rheumatol. (2005) 32(10):1975-1985.
   PubMed Web of Science ®Google Scholar
• ARNOLD LM, LU Y, CROFFORD LJ et al.: A double-blind, multicenter trial comparing duloxetine with placebo in the treatment of fibromyalgia patients with or without major depressive disorder. Arthritis Rheum. (2004) 50(9):2974-2984.
   PubMed Web of Science ®Google Scholar
• ARNOLD LM, ROSEN A, PRITCHETT YL: A randomized, double-blind, placebo-controlled trial of duloxetine in the treatment of women with fibromyalgia with or without major depressive disorder. Pain (2005) 119(1-3):5-15.
   PubMed Web of Science ®Google Scholar
• ALFINITO PD, HUSELTON C, CHEN X, DEECHER DC: Pharmacokinetic and pharmacodynamic profiles of the novel serotonin and norepinephrine reuptake inhibitor desvenlafaxine succinate in ovariectomized Sprague-Dawley rats. Brain Res. (2006) 1098(1):71-78.
   PubMed Web of Science ®Google Scholar
• SAYAR K, AKSU G, AK I, TOSUN M: Venlafaxine treatment of fibromyalgia. Ann. Pharmacother. (2003) 37(11):1561-1565.
   PubMed Web of Science ®Google Scholar
• KENT JM: SNaRIs, NaSSAs and NaRIs: new agents for the treatment of depression. Lancet (2000) 355:911-918.
   PubMed Web of Science ®Google Scholar
• KRELL HV, LEUCHTER AF, COOK IA, ABRAMS M: Evaluation of reboxetine, a noradrenergic antidepressant, for the treatment of fibromyalgia and chronic low back pain. Psychosomatics (2005) 46(5):379-384.
   PubMed Web of Science ®Google Scholar
• SANCHEZ C, HYTTEL J: Comparison of the effects of antidepressants and their metabolites on reuptake of biogenic amines and on receptor binding. Cell Mol. Neurobiol. (1999) 19(4):467-489.
   PubMed Web of Science ®Google Scholar
• SEMENCHUK MR, SHERMAN S, DAVIS B: Double-blind, randomized trial of bupropion SR for the treatment of neuropathic pain. Neurology (2001) 57(9):1583-1588.
   PubMed Web of Science ®Google Scholar
• KATZ J, PENNELLA-VAUGHAN J, HETZEL RD, KANAZI GE, DWORKIN RH: A randomized, placebo-controlled trial of bupropion sustained release in chronic low back pain. J. Pain (2005) 6(10):656-661.
   PubMed Web of Science ®Google Scholar
• VOLKOW ND, WANG GJ, FOWLER JS et al.: The slow and long-lasting blockade of dopamine transporters in human brain induced by the new antidepressant drug radafaxine predict poor reinforcing effects. Biol. Psychiatry (2005) 57(6):640-646.
   PubMed Web of Science ®Google Scholar
• BENNETT RM, JONES J, TURK DC, RUSSELL IJ, MATALLANA L: An internet survey of 2,596 people with fibromyalgia. BMC Musculoskelet. Disord. (2007) 8:27.
   PubMed Web of Science ®Google Scholar
• FRINK MC, HENNIES HH, ENGLBERGER W, HAURAND M, WILFFERT B: Influence of tramadol on neurotransmitter systems of the rat brain. Arzneimittelforschung (1996) 46(11):1029-1036.
   PubMed Web of Science ®Google Scholar
• RAFFA RB, FRIDERICHS E, REIMANN W et al.: Complementary and synergistic antinociceptive interaction between the enantiomers of tramadol. J. Pharmacol. Exp. Ther. (1993) 267(1):331-340.
   PubMed Web of Science ®Google Scholar
• BIASI G, MANCA S, MANGANELLI S, MARCOLONGO R: Tramadol in the fibromyalgia syndrome: a controlled clinical trial versus placebo. Int. J. Clin. Pharmacol. Res. (1998) 18(1):13-19.
   PubMedGoogle Scholar
• RUSSELL IJ, KAMIN M, BENNETT RM, SCHNITZER TJ, GREEN JA, WARREN A: Efficacy of tramadol in treatment of pain in fibromyalgia. J. Clin. Rheum. (2000) 6(5):250-257.
   PubMed Web of Science ®Google Scholar
• BENNETT RM, KAMIN M, KARIM R, ROSENTHAL N: Tramadol and acetaminophen combination tablets in the treatment of fibromyalgia pain: a double-blind, randomized, placebo-controlled study. Am. J. Med. (2003) 114(7):537-545.
   PubMed Web of Science ®Google Scholar
• BENNETT RM, SCHEIN J, KOSINSKI MR, HEWITT DJ, JORDAN DM, ROSENTHAL NR: Impact of fibromyalgia pain on health-related quality of life before and after treatment with tramadol/acetaminophen. Arthritis Rheum. (2005) 53(4):519-527.
   PubMed Web of Science ®Google Scholar
• SPATH M, STRATZ T, FARBER L, HAUS U, PONGRATZ D: Treatment of fibromyalgia with tropisetron – dose and efficacy correlations. Scand. J. Rheumatol. Suppl. (2004) 119:63-66.
   PubMedGoogle Scholar
• FARBER L, STRATZ T, BRUCKLE W et al.: Efficacy and tolerability of tropisetron in primary fibromyalgia – a highly selective and competitive 5-HT3 receptor antagonist. German Fibromyalgia Study Group. Scand. J. Rheumatol. Suppl. (2000) 113:49-54.
   PubMedGoogle Scholar
• HAUS U, VARGA B, STRATZ T, SPATH M, MULLER W: Oral treatment of fibromyalgia with tropisetron given over 28 days: influence on functional and vegetative symptoms, psychometric parameters and pain. Scand. J. Rheumatol. Suppl. (2000) 113:55-58.
   PubMedGoogle Scholar
• CROFFORD LJ, ROWBOTHAM MC, MEASE PJ et al.: Pregabalin for the treatment of fibromyalgia syndrome: results of a randomized, double-blind, placebo-controlled trial. Arthritis Rheum. (2005) 52(4):1264-1273.
   PubMed Web of Science ®Google Scholar
• WOOD PB: A reconsideration of the relevance of systemic low-dose ketamine to the pathophysiology of fibromyalgia. J. Pain (2006) 7(9):611-614.
   PubMed Web of Science ®Google Scholar
• DZIEDZICKA-WASYLEWSKA M, FERRARI F, JOHNSON RD et al.: Mechanisms of action of pramipexole: effects of receptors. Rev. Contemp. Pharmacother. (2001) 12(1):1-31.
   Web of Science ®Google Scholar
• KAYE CM, NICHOLLS B: Clinical pharmacokinetics of ropinirole. Clin. Pharmacokinet. (2000) 39(4):243-254.
   PubMed Web of Science ®Google Scholar
• HOLMAN AJ, NEIMAN RA, ETTLINGER RE: Preliminary efficacy of the dopamine against, pramipexole for fibromyalgia: the first, open label, multicenter experience. J. Musculoskeletal Pain (2004) 12(1):69-74.
   Web of Science ®Google Scholar
• HOLMAN AJ: Ropinirole, a dopamine agonist, for refractory fibromyalgia: preliminary observations. J. Clin. Rheum. (2003) 9(4):277-279.
   PubMed Web of Science ®Google Scholar
• HOLMAN AJ, MYERS RR: A randomized, double-blind, placebo-controlled trial of pramipexole, a dopamine agonist, in patients with fibromyalgia receiving concomitant medications. Arthritis Rheum. (2005) 52(8):2495-2505.
   PubMed Web of Science ®Google Scholar
• LIN SC, KAPLAN J, BURGER CD, FREDRICKSON PA: Effect of pramipexole in treatment of resistant restless legs syndrome. Mayo Clin. Proc. (1998) 73(6):497-500.
   PubMed Web of Science ®Google Scholar
• SOMERS VK, DYKEN ME, CLARY MP, ABBOUD FM: Sympathetic neural mechanisms in obstructive sleep apnea. Am. J. Respir. Crit. Care Med. (1995) 96:1897-1904.
   Google Scholar
• O’DRISCOLL DM, MORRELL MJ: The interaction between respiratory and autonomic function during sleep related changes in pharyngeal airway patency. Auton. Neurosci. (2005) 120(1-2):18-25.
   PubMed Web of Science ®Google Scholar
• KARLSSON AK: Autonomic dysfunction in spinal cord injury: clinical presentation of symptoms and signs. Prog. Brain Res. (2006) 152:1-8.
   PubMed Web of Science ®Google Scholar
• HOLMAN AJ: Treatment of fibromyalgia with the dopamine agonist ropinirole: a 14-week double-blind, pilot, randomized controlled trial with 14-week blinded extension. Arthritis Rheum (2004) 50(9):S698 (Abstract).
   Google Scholar
• COMELLA CL: Restless legs syndrome: treatment with dopaminergic agents. Neurology (2002) 58(4 Suppl. 1):S87-S92.
   PubMed Web of Science ®Google Scholar
• WOOD PB: Mesolimbic dopaminergic mechanisms and pain control. Pain (2006) 120(3):230-234.
   PubMed Web of Science ®Google Scholar
• MAITRE M: The γ-hydroxybutyrate signalling system in brain: organization and functional implications. Prog. Neurobiol. (1997) 51(3):337-361.
   PubMed Web of Science ®Google Scholar
• SCHARF MB, HAUCK M, STOVER R, MCDANNOLD M, BERKOWITZ D: Effect of γ-hydroxybutyrate on pain, fatigue, and the α sleep anomaly in patients with fibromyalgia. Preliminary report. J. Rheumatol. (1998) 25(10):1986-1990.
   PubMed Web of Science ®Google Scholar
• SCHARF MB, BAUMANN M, BERKOKWITZ D: The effects of sodium oxybate on clinical symptoms and sleep patterns in patients with fibromyalgia. J. Rheumatol. (2003) 30(5):1070-1074.
   PubMed Web of Science ®Google Scholar
• RUSSELL IJ, BENNETT RM, MICHALEK JE, OXYBATE FOR FMS STUDY GROUP: Sodium oxybate relieves pain and improves sleep in fibromyalgia syndrome [FMS]: a randomized, double-blind, placebo-controlled, multi-center clinical trial. 69th Annual Meeting of the American College of Rheumatology. San Diego, USA (13 – 17 November 2005):L30 (Abstract).
   Google Scholar
• WOOD PB: A randomized double-blind, placebo-controlled, parallel-group, multicenter trial comparing the effects of orally administered Xyrem (sodium oxybate) with placebo for the treatment of fibromyalgia. Pain Med. (2006) 7(2):181-182 (Abstract).
   Google Scholar
• MOLDOFSKY H, SCARISBRICK P, ENGLAND R, SMYTHE H: Musculoskeletal symptoms and non-REM sleep disturbance in patients with ‘fibrositis syndrome’ and healthy subjects. Psychosom. Med. (1975) 37(4):341-351.
   PubMed Web of Science ®Google Scholar
• MOLDOFSKY H, SCARISBRICK P: Induction of neurasthenic musculoskeletal pain syndrome by selective sleep stage deprivation. Psychosom. Med. (1976) 38(1):35-44.
   PubMed Web of Science ®Google Scholar
• WALTERS JR, ROTH RH: Effect of hydroxybutyrate on dopamine and dopamine metabolites in the rat striatum. Biochem. Pharmacol. (1972) 21(15):2111-2121.
   PubMed Web of Science ®Google Scholar
• DA PRADA M, KELLER HH: Baclofen and γ-hydroxybutyrate: similar effects on cerebral dopamine neurons. Life Sci. (1976) 19(8):1253-1264.
   PubMed Web of Science ®Google Scholar
• FEIGENBAUM JJ, HOWARD SG: Nalaxone reverses the inhibitory effect of γ-hydroxybutyrate on central DA release in vivo in awake animals: a microdialysis study. Neurosci. Lett. (1997) 224(1):71-74.
   PubMed Web of Science ®Google Scholar
• HARRIS NC, WEBB C, GREENFIELD SA: The effects of γ-hydroxybutyrate on the membrane properties of guinea-pig pars compacta neurons in the substantia nigra in vitro. Neuroscience (1989) 31(2):363-370.
   PubMed Web of Science ®Google Scholar
• MADDEN TE, JOHNSON SW: Η-hydroxybutyrate is a GABA-B receptor agonist that increases a potassium conductance in rat ventral tegmental dopamine neurons. J. Pharmacol. Exp. Ther. (1998) 287(1):261-265.
   PubMed Web of Science ®Google Scholar
• BENNETT RM, CLARK SC, WALCZYK J: A randomized, double-blind, placebo-controlled study of growth hormone in the treatment of fibromyalgia. Am. J. Med. (1998) 104(3):227-231.
   PubMed Web of Science ®Google Scholar
• JONES KD, BURCKHARDT CS, DEODHAR AA, PERRIN NA, HANSON G, BENNETT RM: Pyridostigmine normalizes growth hormone response to acute exercise in fibromyalgia patients, but is not superior to exercise for symptom control. Arthritis Rheum. (2005) 52(9):S267.
   Google Scholar
• VALKEINEN H, HAKKINEN A, HANNONEN P, HAKKINEN K, ALEN M: Acute heavy-resistance exercise-induced pain and neuromuscular fatigue in elderly women with fibromyalgia and in healthy controls: effects of strength training. Arthritis Rheum. (2006) 54(4):1334-1339.
   PubMed Web of Science ®Google Scholar
• PATCHETT AA, NARGUND RP, TATA JR et al.: Design and biological activities of L-163,191 (MK-0677): a potent, orally active growth hormone secretagogue. Proc. Natl. Acad. Sci. USA (1995) 92(15):7001-7005.
   PubMed Web of Science ®Google Scholar
• RUSSO EB: Clinical endocannabinoid deficiency (CECD): can this concept explain therapeutic benefits of cannabis in migraine, fibromyalgia, irritable bowel syndrome and other treatment-resistant conditions? Neuro. Endocrinol. Lett. (2004) 25(1-2):31-39.
   PubMed Web of Science ®Google Scholar
• KO G, WINE W: Chronic pain and cannabinoids. Practical Pain Management (2005) 5(4):28-39.
   Google Scholar
• FAN P: Cannabinoid agonists inhibit the activation of 5-HT3 receptors in rat nodose ganglion neurons. J. Neurophysiol. (1995) 73(2):907-910.
   PubMed Web of Science ®Google Scholar
• CARTA G, GESSA GL, NAVA F: Dopamine D2 receptor antagonists prevent Δ9-tetrahydrocannabinol-induced antinociception in rats. Eur. J. Pharmacol. (1999) 384(2-3):153-156.
   PubMed Web of Science ®Google Scholar
• SHEN M, PISER TM, SEYBOLD VS, THAYER SA: Cannabinoid receptor agonists inhibit glutamatergic synaptic transmission in rat hippocampal cultures. J. Neurosci. (1996) 16(14):4322-4334.
   PubMed Web of Science ®Google Scholar